HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned
Benzinga Newsdesk 5 days ago
News
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside very
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
— Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population —
— Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR-mutated lung cancer patients —